Skip to content
A Green Sign – Lifestyle
Author:
Atavistik Bio, Inc.
Atavistik Bio Appoints Habib Dable to its Board of Directors
July 29, 2026
Atavistik Bio Announces U.S. FDA Clearance of Investigational New Drug Application and Fast Track Designation for ATV-1601 for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
June 9, 2026
Atavistik Bio Closes $40 Million Series B Extension for Advancement of its Pipeline Bringing Total Round Proceeds to $160 Million
March 6, 2026